DrugPatentWatch Database Preview
Details for Patent: 9,339,504
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 9,339,504 protect, and when does it expire?
Patent 9,339,504 protects LAMICTAL ODT and is included in one NDA.
This patent has eighteen patent family members in thirteen countries.
Summary for Patent: 9,339,504
| Title: | Orally disintegrating tablet compositions of lamotrigine |
| Abstract: | The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients. |
| Inventor(s): | Venkatesh; Gopi M. (Vandalia, OH), Vyas; Nehal H. (Yardley, PA), Gosselin; Michael (Springboro, OH), Lai; Jin-Wang (Springboro, OH) |
| Assignee: | ADARE PHARMACEUTICALS, INC. (Lawrenceville, NJ) |
| Application Number: | 14/172,962 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,339,504
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | LAMICTAL ODT | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 022251-001 | May 8, 2009 | AB | RX | Yes | No | Start Trial | Start Trial | Y | LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | Start Trial | ||
| Glaxosmithkline Llc | LAMICTAL ODT | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 022251-004 | May 8, 2009 | AB | RX | Yes | No | Start Trial | Start Trial | Y | LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,339,504
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 068185 | Start Trial | |||
| Australia | 2008272871 | Start Trial | |||
| Brazil | PI0814408 | Start Trial | |||
| Canada | 2693072 | Start Trial | |||
| Chile | 2008001966 | Start Trial | |||
| China | 101801192 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
